Moreover, emerging biologic therapies targeting JAK2/STAT3 signaling have demonstrated efficacy in reducing disease activity and inducing clinical remission in patients with moderate to severe IBD [6, 7]. Here, JAK2 is linked to inflammatory bowel disease.